Xenon Pharmaceuticals Inc. (XENE) DCF Valuation

Xenon Pharmaceuticals Inc. (Xene) DCF -Bewertung

CA | Healthcare | Biotechnology | NASDAQ
Xenon Pharmaceuticals Inc. (XENE) DCF Valuation
  • Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • Professional Design: Trusted, Industry-Standard Templates
  • Pre-Built For Quick And Efficient Use
  • No Expertise Is Needed; Easy To Follow

Xenon Pharmaceuticals Inc. (XENE) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Bewerten Sie den finanziellen Ausblick von Xenon Pharmaceuticals Inc. (Xene) mit Fachwissen! Dieser (Xene) DCF-Rechner liefert vorgefüllte Finanzdaten und ermöglicht es Ihnen, das Umsatzwachstum, WACC, Margen und andere kritische Annahmen anzupassen, um sich mit Ihren Vorhersagen auszurichten.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2020
AY2
2021
AY3
2022
AY4
2023
AY5
2024
FY1
2025
FY2
2026
FY3
2027
FY4
2028
FY5
2029
Revenue 32.2 18.4 9.4 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 -42.68 -48.83 -100 0 -47.88 -47.88 -47.88 -47.88 -47.88
EBITDA -28.0 -78.1 -127.5 -210.5 -279.3 .0 .0 .0 .0 .0
EBITDA, % -86.94 -423.53 -1351.7 100 100 -17.39 -17.39 -17.39 -17.39 -17.39
Depreciation .6 .9 1.6 3.5 .0 .0 .0 .0 .0 .0
Depreciation, % 2 4.91 17.21 100 100 44.83 44.83 44.83 44.83 44.83
EBIT -28.6 -79.0 -129.1 -214.1 -279.3 .0 .0 .0 .0 .0
EBIT, % -88.94 -428.45 -1368.91 100 100 -17.79 -17.79 -17.79 -17.79 -17.79
Total Cash 177.0 551.8 592.1 638.1 626.9 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 1.8 2.8 1.0 .9 1.5
Account Receivables, % 5.66 15 10.45 100 100
Inventories -1.8 -2.8 -1.0 .0 .0 .0 .0 .0 .0 .0
Inventories, % -5.66 -15 -10.45 100 100 33.78 33.78 33.78 33.78 33.78
Accounts Payable 3.0 3.8 8.5 8.6 .0 .0 .0 .0 .0 .0
Accounts Payable, % 9.45 20.74 90 100 100 64.04 64.04 64.04 64.04 64.04
Capital Expenditure -2.6 -2.1 -2.9 -5.6 .0 .0 .0 .0 .0 .0
Capital Expenditure, % -8.2 -11.12 -30.68 100 100 -10 -10 -10 -10 -10
Tax Rate, % 1.72 1.72 1.72 1.72 1.72 1.72 1.72 1.72 1.72 1.72
EBITAT -28.4 -79.0 -129.3 -213.7 -274.5 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -27.3 -79.3 -125.9 -216.6 -283.7 1.5 .0 .0 .0 .0
WACC, % 9.71 9.71 9.71 9.71 9.71 9.71 9.71 9.71 9.71 9.71
PV UFCF
SUM PV UFCF 1.3
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value 1
Net Debt -134
Equity Value 135
Diluted Shares Outstanding, MM 78
Equity Value Per Share 1.73

What You Will Get

  • Real Xenon Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Xenon Pharmaceuticals Inc. (XENE).
  • Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates to fit your analysis needs.
  • Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Xenon’s fair value.
  • Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections specifically for Xenon Pharmaceuticals Inc. (XENE).
  • Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility in your financial assessments.

Key Features

  • Comprehensive XENE Data: Pre-loaded with Xenon Pharmaceuticals' historical performance and future projections.
  • Fully Customizable Inputs: Modify revenue growth rates, profit margins, discount rates, tax implications, and capital investments.
  • Dynamic Valuation Model: Automatic recalculations of Net Present Value (NPV) and intrinsic value based on user-defined parameters.
  • Scenario Analysis: Develop various forecasting scenarios to evaluate different valuation results.
  • User-Friendly Interface: Intuitive, organized, and suitable for both industry experts and newcomers.

How It Works

  1. Step 1: Download the Excel file.
  2. Step 2: Review pre-entered Xenon Pharmaceuticals Inc. (XENE) data (historical and projected).
  3. Step 3: Adjust key assumptions (yellow cells) based on your analysis.
  4. Step 4: View automatic recalculations for Xenon Pharmaceuticals Inc. (XENE)’s intrinsic value.
  5. Step 5: Use the outputs for investment decisions or reporting.

Why Choose This Calculator for Xenon Pharmaceuticals Inc. (XENE)?

  • User-Friendly Interface: Crafted to cater to both novice users and seasoned professionals.
  • Customizable Inputs: Adjust parameters effortlessly to fit your financial analysis needs.
  • Real-Time Valuation: Watch as changes in inputs instantly reflect on Xenon’s valuation.
  • Pre-Loaded Data: Comes equipped with Xenon’s latest financial information for swift evaluations.
  • Endorsed by Experts: A preferred tool among investors and analysts for strategic decision-making.

Who Should Use This Product?

  • Pharmaceutical Students: Understand drug development processes and apply them using real-world data.
  • Researchers: Integrate advanced models into studies or clinical research.
  • Investors: Validate your investment strategies and evaluate valuation metrics for Xenon Pharmaceuticals Inc. (XENE).
  • Analysts: Enhance your analysis with a customizable financial model tailored for biotech firms.
  • Healthcare Entrepreneurs: Discover how large pharmaceutical companies like Xenon are evaluated and analyzed.

What the Template Contains

  • Preloaded XENE Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
  • DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
  • Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
  • Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
  • Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
  • Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.